TaxTMI 
TaxTMI 
Sigachi Industries aims to increase Revenue Potential by INR 250 cr Commencing from Q427
X X X X Extracts X X X X
X X X X Extracts X X X X
....igachi Industries aims to increase Revenue Potential by INR 250 cr Commencing from Q427<BR>PTI News<BR>Dated:- 23-1-2026<BR>PTI<BR>Hyderabad, January 23, 2026: Sigachi Industries Ltd. (NSE: SIGACHI; BSE: 543389), a leading Indian pharmaceutical company, today announced a significant milestone in its research and development pipeline with the successful advancement of a new Cystic Fibrosis (CF) Act....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ive Pharmaceutical Ingredients (APIs) combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The development marks an important step in Sigachi’s strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments. The global cystic fibrosis therapeutics market is estimated to exceed....
X X X X Extracts X X X X
X X X X Extracts X X X X
.... USD 10 billion, driven by growing adoption of next-generation modulator therapies, long-term treatment requirements, and strong pricing resilience. Against this backdrop, Sigachi’s entry into CF APIs positions the Company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility. Based on internal market assessment and strategic evaluation, the Company i....
X X X X Extracts X X X X
X X X X Extracts X X X X
....s actively exploring strategic collaborations with formulation innovators for R&D and future commercial supply of these CF APIs. Subject to successful partnerships and market progression, the Company estimates a revenue potential of approximately ?250 crore per annum commencing from Q4 FY2026–27, making this portfolio a meaningful growth driver. Commenting on the development, Lijo Chacko, Depu....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ty Group CEO, Sigachi Industries Limited, said, “This milestone reflects Sigachi’s focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders.” The CF API combination inv....
X X X X Extracts X X X X
X X X X Extracts X X X X
....olves advanced chemistry, multi-step synthesis, and specialised reactions, resulting in high technological complexity and significant barriers to entry, thereby limiting competitive intensity and reinforcing Sigachi’s capabilities in complex API manufacturing. Further strengthening long-term visibility, the innovator patent protection for Vanzacaftor extends until 2039, providing sustained col....
X X X X Extracts X X X X
X X X X Extracts X X X X
....laboration-led commercial opportunity and revenue stability within the cystic fibrosis therapeutic space. Sigachi Industries continues to focus on strengthening its core businesses while selectively scaling innovation-driven, high-value opportunities aligned with its long-term growth strategy. About Sigachi Industries Ltd Sigachi Industries Limited is a global player in the pharmaceutical indu....
X X X X Extracts X X X X
X X X X Extracts X X X X
....stry dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services. The company's diverse product portfolio is manufactured in 5 multilocational facilities, viz. Telangana, Gujarat, and Karnataka. Aligned with its ethos of customer centricity, Sigachi established subsidiaries in UAE ....
X X X X Extracts X X X X
X X X X Extracts X X X X
....and USA to be closer to its clients and improve responsiveness. With a strong focus on innovation, quality, and regulatory compliance, we leverage cutting-edge technology and global expertise to develop high-value pharma, food and nutrition solutions that enhance healthcare outcomes. Committed to excellence, we continuously invest in Research and Development, ensuring the highest standards of qual....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ity and safety. With 36 years of industry experience, Sigachi is a trusted partner for pharmaceutical and nutraceutical companies spread across 65+ countries. At Sigachi, we collaborate with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients. (Disclaimer: The above press release comes to you under an arrangement w....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ith NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR<BR> News - Press release - PIB ....